Transcription factors and hormone receptors: Sex‑specific targets for cancer therapy (Review)
- Authors:
- Juyeon Kim
- Hyobin Bang
- Cheyun Seong
- Eun-Sook Kim
- Sun Young Kim
-
Affiliations: Department of Chemistry, College of Science and Technology, Duksung Women's University, Seoul 01369, Republic of Korea, College of Pharmacy, Duksung Women's University, Seoul 01369, Republic of Korea - Published online on: December 6, 2024 https://doi.org/10.3892/ol.2024.14839
- Article Number: 93
-
Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Shen X, Jain A, Aladelokun O, Yan H, Gilbride A, Ferrucci LM, Lu L, Khan SA and Johnson CH: Asparagine, colorectal cancer, and the role of sex, genes, microbes, and diet: A narrative review. Front Mol Biosci. 9:9586662022. View Article : Google Scholar : PubMed/NCBI | |
|
Fuentes N, Silva Rodriguez M and Silveyra P: Role of sex hormones in lung cancer. Exp Biol Med (Maywood). 246:2098–2110. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Coelingh Bennink HJT, Prowse A, Egberts JFM, Debruyne FMJ, Huhtaniemi IT and Tombal B: The loss of estradiol by androgen deprivation in prostate cancer patients shows the importance of estrogens in males. J Endocr Soc. 8:bvae1072024. View Article : Google Scholar : PubMed/NCBI | |
|
Frederiksen H, Johannsen TH, Andersen SE, Albrethsen J, Landersoe SK, Petersen JH, Andersen AN, Vestergaard ET, Schorring ME, Linneberg A, et al: Sex-specific estrogen levels and reference intervals from infancy to late adulthood determined by LC-MS/MS. J Clin Endocrinol Metab. 105:754–768. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gates MA, Mekary RA, Chiu GR, Ding EL, Wittert GA and Araujo AB: Sex steroid hormone levels and body composition in men. J Clin Endocrinol Metab. 98:2442–2450. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Marriott RJ, Murray K, Adams RJ, Antonio L, Ballantyne CM, Bauer DC, Bhasin S, Biggs ML, Cawthon PM, Couper DJ, et al: Factors associated with circulating sex hormones in men: Individual participant data meta-analyses. Ann Intern Med. 176:1221–1234. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Simpson ER, Misso M, Hewitt KN, Hill RA, Boon WC, Jones ME, Kovacic A, Zhou J and Clyne CD: Estrogen-the good, the bad, and the unexpected. Endocr Rev. 26:322–330. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gandhi N, Omer S and Harrison RE: In vitro cell culture model for osteoclast activation during estrogen withdrawal. Int J Mol Sci. 25:61342024. View Article : Google Scholar : PubMed/NCBI | |
|
Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR and Boyce BF: Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med. 2:1132–1136. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP and Pacifici R: Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem. 276:8836–8840. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Gavali S, Gupta MK, Daswani B, Wani MR, Sirdeshmukh R and Khatkhatay MI: LYN, a key mediator in estrogen-dependent suppression of osteoclast differentiation, survival, and function. Biochim Biophys Acta Mol Basis Dis. 1865:547–557. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kharb R, Haider K, Neha K and Yar MS: Aromatase inhibitors: Role in postmenopausal breast cancer. Arch Pharm (Weinheim). 353:e20000812020. View Article : Google Scholar : PubMed/NCBI | |
|
Arumugam A, Lissner EA and Lakshmanaswamy R: The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model. Reprod Biol Endocrinol. 12:662014. View Article : Google Scholar : PubMed/NCBI | |
|
Parish SJ, Simon JA, Davis SR, Giraldi A, Goldstein I, Goldstein SW, Kim NN, Kingsberg SA, Morgentaler A, Nappi RE, et al: International society for the study of women's sexual health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. J Sex Med. 18:849–867. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Van-Duyne G, Blair IA, Sprenger C, Moiseenkova-Bell V, Plymate S and Penning TM: The androgen receptor. Vitam Horm. 123:439–481. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai CC, Yang YSH, Chen YF, Huang LY, Yang YN, Lee SY, Wang WL, Lee HL, Whang-Peng J, Lin HY, et al: Integrins and actions of androgen in breast cancer. Cells. 12:21262023. View Article : Google Scholar : PubMed/NCBI | |
|
Naamneh Elzenaty R, du Toit T and Flück CE: Basics of androgen synthesis and action. Best Pract Res Clin Endocrinol Metab. 36:1016652022. View Article : Google Scholar : PubMed/NCBI | |
|
Bienenfeld A, Azarchi S, Lo Sicco K, Marchbein S, Shapiro J and Nagler AR: Androgens in women: Androgen-mediated skin disease and patient evaluation. J Am Acad Dermatol. 80:1497–1506. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang R, Hu K, Bai H, Liu H, Pu Y, Yang C, Liu Q and Fan P: Increased oxidative stress is associated with hyperandrogenemia in polycystic ovary syndrome evidenced by oxidized lipoproteins stimulating rat ovarian androgen synthesis in vitro. Endocrine. 84:1238–1249. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Paakinaho V and Palvimo JJ: Genome-wide crosstalk between steroid receptors in breast and prostate cancers. Endocr Relat Cancer. 28:R231–R250. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Amirghofran Z, Monabati A and Gholijani N: Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer. Pathol Oncol Res. 10:37–41. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Bodner K, Laubichler P, Kimberger O, Czerwenka K, Zeillinger R and Bodner-Adler B: Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. Anticancer Res. 30:1341–1345. 2010.PubMed/NCBI | |
|
Yoon K, Park Y, Kang E, Kim E, Kim JH, Kim SH, Suh KJ, Kim SM, Jang M, Yun BR, et al: Effect of estrogen receptor expression level and hormonal therapy on prognosis of early breast cancer. Cancer Res Treat. 54:1081–1090. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging. CA Cancer J Clin. 67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Giuliano AE, Edge SB and Hortobagyi GN: Eighth edition of the AJCC cancer staging manual: Breast cancer. Ann Surg Oncol. 25:1783–1785. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 121:2750–2767. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Huggins C and Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 167:948–952. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Scher HI and Sawyers CL: Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 23:8253–8261. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, et al: Hormonal modulation of ESR1 mutant metastasis. Oncogene. 40:997–1011. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kolyvas EA, Caldas C, Kelly K and Ahmad SS: Androgen receptor function and targeted therapeutics across breast cancer subtypes. Breast Cancer Res. 24:792022. View Article : Google Scholar : PubMed/NCBI | |
|
Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL, et al: Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 69:6131–6140. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, Jindal S, Hui M, Finlay-Schultz J, Ebrahimie E, et al: The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat Med. 27:310–320. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Secreto G, Girombelli A and Krogh V: Androgen excess in breast cancer development: Implications for prevention and treatment. Endocr Relat Cancer. 26:R81–R94. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Gehrig J, Kaulfuß S, Jarry H, Bremmer F, Stettner M, Burfeind P and Thelen P: Prospects of estrogen receptor β activation in the treatment of castration-resistant prostate cancer. Oncotarget. 8:34971–34979. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lung DK, Reese RM and Alarid ET: Intrinsic and extrinsic factors governing the transcriptional regulation of ESR1. Horm Cancer. 11:129–147. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jensen EV, Desombre ER, Kawashima T, Suzuki T, Kyser K and Jungblut PW: Estrogen-binding substances of target tissues. Science. 158:529–530. 1967. View Article : Google Scholar : PubMed/NCBI | |
|
Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, et al: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1491–1494. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Bunone G, Briand PA, Miksicek RJ and Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15:2174–2183. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Tremblay A, Tremblay GB, Labrie F and Giguère V: Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell. 3:513–519. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Yi P, Wang Z, Feng Q, Pintilie GD, Foulds CE, Lanz RB, Ludtke SJ, Schmid MF, Chiu W and O'Malley BW: Structure of a biologically active estrogen receptor-coactivator complex on DNA. Mol Cell. 57:1047–1058. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engström O, Ohman L, Greene GL, Gustafsson JA and Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389:753–758. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Heery DM, Kalkhoven E, Hoare S and Parker MG: A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 387:733–736. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK and Rosenfeld MG: The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature. 387:677–684. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar R, Betney R, Li J, Thompson EB and McEwan IJ: Induced alpha-helix structure in AF1 of the androgen receptor upon binding transcription factor TFIIF. Biochemistry. 43:3008–3013. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Bevan CL, Hoare S, Claessens F, Heery DM and Parker MG: The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol. 19:8383–8392. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Huang B, Omoto Y, Iwase H, Yamashita H, Toyama T, Coombes RC, Filipovic A, Warner M and Gustafsson JÅ: Differential expression of estrogen receptor alpha, beta1, and beta2 in lobular and ductal breast cancer. Proc Natl Acad Sci USA. 111:1933–1938. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Couse JF and Korach KS: Estrogen receptor null mice: What have we learned and where will they lead us? Endocr Rev. 20:358–417. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Jia M, Dahlman-Wright K and Gustafsson JÅ: Estrogen receptor alpha and beta in health and disease. Best Pract Res Clin Endocrinol Metab. 29:557–568. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Martin EC, Conger AK, Yan TJ, Hoang VT, Miller DF, Buechlein A, Rusch DB, Nephew KP, Collins-Burow BM and Burow ME: MicroRNA-335-5p and −3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance. FEBS Lett. 591:382–392. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Santner SJ, Feil PD and Santen RJ: In situ estrogen production via the estrone sulfatase pathway in breast tumors: Relative importance versus the aromatase pathway. J Clin Endocrinol Metab. 59:29–33. 1984. View Article : Google Scholar : PubMed/NCBI | |
|
Jordan VC: Antiestrogenic action of raloxifene and tamoxifen: Today and tomorrow. J Natl Cancer Inst. 90:967–971. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK and Elledge RM: Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 97:1254–1261. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Horwitz KB, Koseki Y and McGuire WL: Estrogen control of progesterone receptor in human breast cancer: Role of estradiol and antiestrogen. Endocrinology. 103:1742–1751. 1978. View Article : Google Scholar : PubMed/NCBI | |
|
Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R and Baum M: Estrogen receptor status, progesterone receptor status, and HER2 status as biomarkers for predicting response to endocrine therapy. J Clin Oncol. 26:1814–1820. 2008. | |
|
Kumar R, Zakharov MN, Khan SH, Miki R, Jang H, Toraldo G, Singh R, Bhasin S and Jasuja R: The dynamic structure of the estrogen receptor. J Amino Acids. 2011:8125402011. View Article : Google Scholar : PubMed/NCBI | |
|
Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M and Gustafsson JA: Update on estrogen signaling. FEBS Lett. 546:17–24. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Flouriot G, Brand H, Denger S, Metivier R, Kos M, Reid G, Sonntag-Buck V and Gannon F: Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO J. 19:4688–4700. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Langley RE, Godsland IF, Kynaston H, Clarke NW, Rosen SD, Morgan RC, Pollock P, Kockelbergh R, Lalani EN, Dearnaley D, et al: Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int. 102:442–445. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lau KM and To KF: Importance of estrogenic signaling and its mediated receptors in prostate cancer. Int J Mol Sci. 17:14342016. View Article : Google Scholar : PubMed/NCBI | |
|
Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y and Risbridger GP: Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J. 22:1512–1520. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Olczak M, Orzechowska MJ, Bednarek AK and Lipiński M: The transcriptomic profiles of ESR1 and MMP3 stratify the risk of biochemical recurrence in primary prostate cancer beyond clinical features. Int J Mol Sci. 24:83992023. View Article : Google Scholar : PubMed/NCBI | |
|
Lin Q, Cao J, Du X, Yang K, Yang X, Liang Z, Shi J and Zhang J: CYP1B1-catalyzed 4-OHE2 promotes the castration resistance of prostate cancer stem cells by estrogen receptor α-mediated IL6 activation. Cell Commun Signal. 20:312022. View Article : Google Scholar : PubMed/NCBI | |
|
Reis LO, Zani EL and García-Perdomo HA: Estrogen therapy in patients with prostate cancer: A contemporary systematic review. Int Urol Nephrol. 50:993–1003. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Christoforou P, Christopoulos PF and Koutsilieris M: The role of estrogen receptor β in prostate cancer. Mol Med. 20:427–434. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, et al: Hormone-receptor expression and ovarian cancer survival: An ovarian tumor tissue analysis consortium study. Lancet Oncol. 14:853–862. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Park SH, Cheung LWT, Wong AST and Leung PCK: Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. Mol Endocrinol. 22:2085–2098. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Chan KK, Leung TH, Chan DW, Wei N, Lau GT, Liu SS, Siu MK and Ngan HY: Targeting estrogen receptor subtypes (ERα and ERβ) with selective ER modulators in ovarian cancer. J Endocrinol. 221:325–336. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Langdon SP, Herrington CS, Hollis RL and Gourley C: Estrogen signaling and its potential as a target for therapy in ovarian cancer. Cancers (Basel). 12:16472020. View Article : Google Scholar : PubMed/NCBI | |
|
He M, Yu W, Chang C, Miyamoto H, Liu X, Jiang K and Yeh S: Estrogen receptor α promotes lung cancer cell invasion via increase of and cross-talk with infiltrated macrophages through the CCL2/CCR2/MMP9 and CXCL12/CXCR4 signaling pathways. Mol Oncol. 14:1779–1799. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel DA, Fedewa SA, Henley SJ, Pollack LA and Jemal A: Proportion of never smokers among men and women with lung cancer in 7 US States. JAMA Oncol. 7:302–304. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu LH, Liu KJ, Tsai MF, Wu CR, Feng AC, Chu NM and Kao SH: Estrogen adversely affects the prognosis of patients with lung adenocarcinoma. Cancer Sci. 106:51–59. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, Rodabough RJ, Chien JW, Wactawski-Wende J, Gass M, et al: Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): A post-hoc analysis of a randomised controlled trial. Lancet. 374:1243–1251. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou J, Teng R, Xu C, Wang Q, Guo J, Xu C, Li Z, Xie S, Shen J and Wang L: Overexpression of ERα inhibits proliferation and invasion of MKN28 gastric cancer cells by suppressing β-catenin. Oncol Rep. 30:1622–1630. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Takano N, Iizuka N, Hazama S, Yoshino S, Tangoku A and Oka M: Expression of estrogen receptor-alpha and -beta mRNAs in human gastric cancer. Cancer Lett. 176:129–135. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Tang W, Liu R, Yan Y, Pan X, Wang M, Han X, Ren H and Zhang Z: Expression of estrogen receptors and androgen receptor and their clinical significance in gastric cancer. Oncotarget. 8:40765–40777. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen P, Li B and Ou-Yang L: Role of estrogen receptors in health and disease. Front Endocrinol (Lausanne). 13:8390052022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J and Iverson D: Estrogen in obesity-associated colon cancer: Friend or foe? Protecting postmenopausal women but promoting late-stage colon cancer. Cancer Causes Control. 23:1767–1773. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang H, Teng R, Wang Q, Zhang X, Wang H, Wang Z, Cao J and Teng L: Transcriptional analysis of estrogen receptor alpha variant mRNAs in colorectal cancers and their matched normal colorectal tissues. J Steroid Biochem Mol Biol. 112:20–24. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Dai B, Geng L, Yu Y, Sui C, Xie F, Shen W, Zheng T and Yang J: Methylation patterns of estrogen receptor α promoter correlate with estrogen receptor α expression and clinicopathological factors in hepatocellular carcinoma. Exp Biol Med (Maywood). 239:883–890. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hou J, Xu J, Jiang R, Wang Y, Chen C, Deng L, Huang X, Wang X and Sun B: Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatology. 57:678–688. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Iyer JK, Kalra M, Kaul A, Payton ME and Kaul R: Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis. World J Gastroenterol. 23:6802–6816. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S and Gustafsson JA: Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 93:5925–5930. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Mal R, Magner A, David J, Datta J, Vallabhaneni M, Kassem M, Manouchehri J, Willingham N, Stover D, Vandeusen J, et al: Estrogen receptor beta (ERβ): A ligand activated tumor suppressor. Front Oncol. 10:5873862020. View Article : Google Scholar : PubMed/NCBI | |
|
Lewandowski S, Kalita K and Kaczmarek L: Estrogen receptor beta. Potential functional significance of a variety of mRNA isoforms. FEBS Lett. 524:1–5. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Hua H, Zhang H, Kong Q and Jiang Y: Mechanisms for estrogen receptor expression in human cancer. Exp Hematol Oncol. 7:242018. View Article : Google Scholar : PubMed/NCBI | |
|
Haldosén LA, Zhao C and Dahlman-Wright K: Estrogen receptor beta in breast cancer. Mol Cell Endocrinol. 382:665–672. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Dalal H, Dahlgren M, Gladchuk S, Brueffer C, Gruvberger-Saal SK and Saal LH: Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors. Sci Rep. 12:46962022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Zhang C, Chen K, Tang H, Tang J, Song C and Xie X: ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer. Breast Cancer Res Treat. 152:255–269. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Grober OM, Mutarelli M, Giurato G, Ravo M, Cicatiello L, De Filippo MR, Ferraro L, Nassa G, Papa MF, Paris O, et al: Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC Genomics. 12:362011. View Article : Google Scholar : PubMed/NCBI | |
|
Hurtado A, Pinós T, Barbosa-Desongles A, López-Avilés S, Barquinero J, Petriz J, Santamaria-Martínez A, Morote J, de Torres I, Bellmunt J, et al: Estrogen receptor beta displays cell cycle-dependent expression and regulates the G1 phase through a non-genomic mechanism in prostate carcinoma cells. Cell Oncol. 30:349–365. 2008.PubMed/NCBI | |
|
Hwang NM and Stabile LP: Estrogen receptor ß in cancer: To ß(e) or not to ß(e)? Endocrinology. 162:bqab1622021. View Article : Google Scholar : PubMed/NCBI | |
|
Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, Gouvin LM, Sharma VM and Mercurio AM: ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: Implications for Gleason grading. Cancer Cell. 17:319–332. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Mak P, Chang C, Pursell B and Mercurio AM: Estrogen receptor β sustains epithelial differentiation by regulating prolyl hydroxylase 2 transcription. Proc Natl Acad Sci USA. 110:4708–4713. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lim W, Cho J, Kwon HY, Park Y, Rhyu MR and Lee Y: Hypoxia-inducible factor 1 alpha activates and is inhibited by unoccupied estrogen receptor beta. FEBS Lett. 583:1314–1318. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chaurasiya S, Widmann S, Botero C, Lin CY, Gustafsson JÅ and Strom AM: Estrogen receptor β exerts tumor suppressive effects in prostate cancer through repression of androgen receptor activity. PLoS One. 15:e02260572020. View Article : Google Scholar : PubMed/NCBI | |
|
Jefferi NES, Shamhari AA, 'Azhar NKZN, Shin JGY, Kharir NAM, Azhar MA, Hamid ZA, Budin SB and Taib IS: The role of ERα and ERβ in castration-resistant prostate cancer and current therapeutic approaches. Biomedicines. 11:8262023. View Article : Google Scholar : PubMed/NCBI | |
|
Leung YK, Lam HM, Wu S, Song D, Levin L, Cheng L, Wu CL and Ho SM: Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer. 17:675–689. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lazennec G: Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett. 231:151–157. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bossard C, Busson M, Vindrieux D, Gaudin F, Machelon V, Brigitte M, Jacquard C, Pillon A, Balaguer P, Balabanian K and Lazennec G: Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer. PLoS One. 7:e447872012. View Article : Google Scholar : PubMed/NCBI | |
|
Verardi L, Fiori J, Andrisano V, Locatelli A, Morigi R, Naldi M, Bertucci C, Strocchi E, Boga C, Micheletti G and Calonghi N: Indole derivative interacts with estrogen receptor beta and inhibits human ovarian cancer cell growth. Molecules. 25:44382020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen W, Xin B, Pang H, Han L, Shen W, Zhao Z, Duan L, Cao P, Liu L and Zhang H: Downregulation of estrogen receptor β inhibits lung adenocarcinoma cell growth. Oncol Rep. 41:2967–2974. 2019.PubMed/NCBI | |
|
Liu S, Hu C, Li M, An J, Zhou W, Guo J and Xiao Y: Estrogen receptor beta promotes lung cancer invasion via increasing CXCR4 expression. Cell Death Dis. 13:702022. View Article : Google Scholar : PubMed/NCBI | |
|
Peri S and Niv Y: Estrogen receptor beta (ERß) in gastric cancer-A systematic review and meta-analysis. Microb Health Dis. 6:e9842024. | |
|
Zhou F, Xu Y, Shi J, Lan X, Zou X, Wang L and Huang Q: Expression profile of E-cadherin, estrogen receptors, and P53 in early-onset gastric cancers. Cancer Med. 5:3403–3411. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou F, Jin J, Zhou L, Wu L, Cao Y, Yan H, Huang Q, Wang L and Zou X: Suppression of estrogen receptor-beta promotes gastric cancer cell apoptosis with induction of autophagy. Am J Transl Res. 12:4397–4409. 2020.PubMed/NCBI | |
|
Gan L, He J, Zhang X, Zhang YJ, Yu GZ, Chen Y, Pan J, Wang JJ and Wang X: Expression profile and prognostic role of sex hormone receptors in gastric cancer. BMC Cancer. 12:5662012. View Article : Google Scholar : PubMed/NCBI | |
|
Caiazza F, Ryan EJ, Doherty G, Winter DC and Sheahan K: Estrogen receptors and their implications in colorectal carcinogenesis. Front Oncol. 5:192015. View Article : Google Scholar : PubMed/NCBI | |
|
Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, Ström A and Gustafsson JA: Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res. 69:6100–6106. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Topi G, Satapathy SR, Dash P, Fred Mehrabi S, Ehrnström R, Olsson R, Lydrup ML and Sjölander A: Tumour-suppressive effect of oestrogen receptor β in colorectal cancer patients, colon cancer cells, and a zebrafish model. J Pathol. 251:297–309. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, Sotiropoulou-Bonikou G and Papavassiliou AG: Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer. 39:1251–1258. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Rudolph A, Toth C, Hoffmeister M, Roth W, Herpel E, Jansen L, Marx A, Brenner H and Chang-Claude J: Expression of oestrogen receptor β and prognosis of colorectal cancer. Br J Cancer. 107:831–839. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Iavarone M, Lampertico P, Seletti C, Donato MF, Ronchi G, Del Ninno E and Colombo M: The clinical and pathogenetic significance of estrogen receptor-beta expression in chronic liver diseases and liver carcinoma. Cancer. 98:529–534. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Yang W, Lu Y, Xu Y, Xu L, Zheng W, Wu Y, Li L and Shen P: Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs). J Biol Chem. 287:40140–40149. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Marzioni M, Torrice A, Saccomanno S, Rychlicki C, Agostinelli L, Pierantonelli I, Rhönnstad P, Trozzi L, Apelqvist T, Gentile R, et al: An oestrogen receptor β-selective agonist exerts anti-neoplastic effects in experimental intrahepatic cholangiocarcinoma. Dig Liver Dis. 44:134–142. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Handelsman DJ: History of androgens and androgen action. Best Pract Res Clin Endocrinol Metab. 36:1016292022. View Article : Google Scholar : PubMed/NCBI | |
|
Brinkmann AO, Faber PW, van Rooij HC, Kuiper GG, Ris C, Klaassen P, van der Korput JA, Voorhorst MM, van Laar JH, Mulder E, et al: The human androgen receptor: Domain structure, genomic organization and regulation of expression. J Steroid Biochem. 34:307–310. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Davey RA and Grossmann M: Androgen receptor structure, function and biology: From bench to bedside. Clin Biochem Rev. 37:3–15. 2016.PubMed/NCBI | |
|
Moilanen A, Rouleau N, Ikonen T, Palvimo JJ and Jänne OA: The presence of a transcription activation function in the hormone-binding domain of androgen receptor is revealed by studies in yeast cells. FEBS Lett. 412:355–358. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Ueda T, Bruchovsky N and Sadar MD: Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem. 277:7076–7085. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Asai S, Goto Y, Tanigawa K, Tomioka Y, Kato M, Mizuno K, Sakamoto S and Seki N: MiR-15b-5p inhibits castration-resistant growth of prostate cancer cells by targeting the muscarinic cholinergic receptor CHRM3. FEBS Lett. 597:1164–1175. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Martin-Caraballo M: Regulation of molecular biomarkers associated with the progression of prostate cancer. Int J Mol Sci. 25:41712024. View Article : Google Scholar : PubMed/NCBI | |
|
Muralidhar A, Gamat-Huber M, Vakkalanka S and McNeel DG: Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy. J Immunother Cancer. 12:e0088482024. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong M, Xu W, Tian P, Zhang Q, Wang Z, Liang L, Zhang Q, Yang Y, Lu Y and Wei GH: An inherited allele confers prostate cancer progression and drug resistance via RFX6/HOXA10-orchestrated TGFβ signaling. Adv Sci (Weinh). 11:e24014922024. View Article : Google Scholar : PubMed/NCBI | |
|
Liu C, Chen B, Xu P, Yang J, Nip C, Wang L, Shen Y, Ning S, Shang Y, Corey E, et al: Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Res Sq [Preprint]. rs.3.rs-4095949. 2024. | |
|
Matsumoto K, Kosaka T, Takeda T, Fukumoto K, Yasumizu Y, Tanaka N, Morita S, Mizuno R, Asanuma H and Oya M: Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI). Int J Clin Oncol. 29:1198–1203. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Shiota M, Ushijima M, Tsukahara S, Nagakawa S, Okada T, Tanegashima T, Kobayashi S, Matsumoto T and Eto M: Oxidative stress in peroxisomes induced by androgen receptor inhibition through peroxisome proliferator-activated receptor promotes enzalutamide resistance in prostate cancer. Free Radic Biol Med. 221:81–88. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Ramírez-de-Arellano A, Pereira-Suárez AL, Rico-Fuentes C, López-Pulido EI, Villegas-Pineda JC and Sierra-Diaz E: Distribution and effects of estrogen receptors in prostate cancer: Associated molecular mechanisms. Front Endocrinol (Lausanne). 12:8115782022. View Article : Google Scholar : PubMed/NCBI | |
|
Palmieri C, Linden H, Birrell SN, Wheelwright S, Lim E, Schwartzberg LS, Dwyer AR, Hickey TE, Rugo HS, Cobb P, et al: Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): A randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. Lancet Oncol. 25:317–325. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Xu F, Xu K, Fan L, Li X, Liu Y, Yang F, Zhu C and Guan X: Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer. Chin Med J (Engl). 137:338–349. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Cuenca-López MD, Montero JC, Morales JC, Prat A, Pandiella A and Ocana A: Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer. 14:3022014. View Article : Google Scholar : PubMed/NCBI | |
|
Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ, Konishi H, Konishi Y, Lauring J, Mohseni M, et al: The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res. 14:R272012. View Article : Google Scholar : PubMed/NCBI | |
|
Chang C, Lee SO, Yeh S and Chang TM: Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. 33:3225–3234. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chadha S, Rao BR, Slotman BJ, van Vroonhoven CC and van der Kwast TH: An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol. 24:90–95. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C and Castagna G: Androgen receptors in ovarian tumors: Correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res. 17:231–237. 1998.PubMed/NCBI | |
|
Kohan-Ivani K, Gabler F, Selman A, Vega M and Romero C: Role of dihydrotestosterone (DHT) on TGF-β1 signaling pathway in epithelial ovarian cancer cells. J Cancer Res Clin Oncol. 142:47–58. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ligr M, Patwa RR, Daniels G, Pan L, Wu X, Li Y, Tian L, Wang Z, Xu R, Wu J, et al: Expression and function of androgen receptor coactivator p44/Mep50/WDR77 in ovarian cancer. PLoS One. 6:e262502011. View Article : Google Scholar : PubMed/NCBI | |
|
Martins FC, Couturier DL, Paterson A, Karnezis AN, Chow C, Nazeran TM, Odunsi A, Gentry-Maharaj A, Vrvilo A, Hein A, et al: Clinical and pathological associations of PTEN expression in ovarian cancer: A multicentre study from the ovarian tumour tissue analysis consortium. Br J Cancer. 123:793–802. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Hu C, Li M, Zhou W, Wang R and Xiao Y: Androgen receptor suppresses lung cancer invasion and increases cisplatin response via decreasing TPD52 expression. Int J Biol Sci. 19:3709–3725. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou J, Wang H, Sun Q, Liu X, Wu Z, Wang X, Fang W and Ma Z: miR-224-5p-enriched exosomes promote tumorigenesis by directly targeting androgen receptor in non-small cell lung cancer. Mol Ther Nucleic Acids. 23:1217–1228. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Tang Y, Liang P, Sun M, Li T, Shen Z and Sha S: Luteolin inhibits A549 cells proliferation and migration by down-regulating androgen receptors. Eur J Med Res. 28:3532023. View Article : Google Scholar : PubMed/NCBI | |
|
Recchia AG, Musti AM, Lanzino M, Panno ML, Turano E, Zumpano R, Belfiore A, Andò S and Maggiolini M: A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells. Int J Biochem Cell Biol. 41:603–614. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Liu B, Zhou M, Li X, Zhang X, Wang Q, Liu L, Yang M, Yang D, Guo Y, Zhang Q, et al: Interrogation of gender disparity uncovers androgen receptor as the transcriptional activator for oncogenic miR-125b in gastric cancer. Cell Death Dis. 12:4412021. View Article : Google Scholar : PubMed/NCBI | |
|
Xia N, Cui J, Zhu M, Xing R and Lu Y: Androgen receptor variant 12 promotes migration and invasion by regulating MYLK in gastric cancer. J Pathol. 248:304–315. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Soleymani Fard S, Yazdanbod M, Sotoudeh M, Bashash D, Mahmoodzadeh H, Saliminejad K, Mousavi SA, Ghaffari SH and Alimoghaddam K: Prognostic and therapeutic significance of androgen receptor in patients with gastric cancer. Onco Targets Ther. 13:9821–9837. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gu S, Honisch S, Kounenidakis M, Alkahtani S, Alarifi S, Alevizopoulos K, Stournaras C and Lang F: Membrane androgen receptor down-regulates c-src-activity and beta-catenin transcription and triggers GSK-3beta-phosphorylation in colon tumor cells. Cell Physiol Biochem. 34:1402–1412. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Alkahtani S: Testosterone induced apoptosis in colon cancer cells is regulated by PI3K/Rac1 signaling. Asian J Androl. 15:831–834. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Rodríguez-Santiago Y, Garay-Canales CA, Nava-Castro KE and Morales-Montor J: Sexual dimorphism in colorectal cancer: Molecular mechanisms and treatment strategies. Biol Sex Differ. 15:482024. View Article : Google Scholar : PubMed/NCBI | |
|
Acosta-Lopez S, Diaz-Bethencourt D, Concepción-Massip T, Martin-Fernandez de Basoa MC, Plata-Bello A, Gonzalez-Rodriguez A, Perez-Hernandez F and Plata-Bello J: The androgen receptor expression and its activity have different relationships with prognosis in hepatocellular carcinoma. Sci Rep. 10:220462020. View Article : Google Scholar : PubMed/NCBI | |
|
Ren QN, Zhang H, Sun CY, Zhou YF, Yang XF, Long JW, Li XX, Mai SJ, Zhang MY, Zhang HZ, et al: Phosphorylation of androgen receptor by mTORC1 promotes liver steatosis and tumorigenesis. Hepatology. 75:1123–1138. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ren H, Ren B, Zhang J, Zhang X, Li L, Meng L, Li Z, Li J, Gao Y and Ma X: Androgen enhances the activity of ETS-1 and promotes the proliferation of HCC cells. Oncotarget. 8:109271–109288. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ouyang X, Feng L, Liu G, Yao L, Wang Z, Liu S, Xiao Y and Zhang G: Androgen receptor (AR) decreases HCC cells migration and invasion via miR-325/ACP5 signaling. J Cancer. 12:1915–1925. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Porter W, Saville B, Hoivik D and Safe S: Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol. 11:1569–1580. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Greaves E, Collins F, Critchley HOD and Saunders PTK: ERβ-dependent effects on uterine endothelial cells are cell specific and mediated via Sp1. Hum Reprod. 28:2490–2501. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Eisermann K, Broderick CJ, Bazarov A, Moazam MM and Fraizer GC: Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site. Mol Cancer. 12:72013. View Article : Google Scholar : PubMed/NCBI | |
|
Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA, et al: Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 100:815–825. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kohvakka A, Sattari M, Shcherban A, Annala M, Urbanucci A, Kesseli J, Tammela TLJ, Kivinummi K, Latonen L, Nykter M and Visakorpi T: AR and ERG drive the expression of prostate cancer specific long noncoding RNAs. Oncogene. 39:5241–5251. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lombardi AP, Pisolato R, Vicente CM, Lazari MF, Lucas TF and Porto CS: Estrogen receptor beta (ERβ) mediates expression of β-catenin and proliferation in prostate cancer cell line PC-3. Mol Cell Endocrinol. 430:12–24. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Song LN and Gelmann EP: Interaction of beta-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor. J Biol Chem. 280:37853–37867. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Dahlman-Wright K, Qiao Y, Jonsson P, Gustafsson JÅ, Williams C and Zhao C: Interplay between AP-1 and estrogen receptor α in regulating gene expression and proliferation networks in breast cancer cells. Carcinogenesis. 33:1684–1691. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Frønsdal K, Engedal N, Slagsvold T and Saatcioglu F: CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem. 273:31853–31859. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH and Gleave ME: Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem. 272:17485–17494. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Dadiani M, Seger D, Kreizman T, Badikhi D, Margalit R, Eilam R and Degani H: Estrogen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: The role of estrogen receptor alpha and c-Myc. Endocr Relat Cancer. 16:819–834. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL and Leitman DC: Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 64:423–428. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Gao L, Schwartzman J, Gibbs A, Lisac R, Kleinschmidt R, Wilmot B, Bottomly D, Coleman I, Nelson P, McWeeney S and Alumkal J: Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS One. 8:e635632013. View Article : Google Scholar : PubMed/NCBI | |
|
Smart E, Semina SE and Frasor J: Update on the role of NFκB in promoting aggressive phenotypes of estrogen receptor-positive breast cancer. Endocrinology. 161:bqaa1522020. View Article : Google Scholar : PubMed/NCBI | |
|
Mak P, Li J, Samanta S and Mercurio AM: ERβ regulation of NF-kB activation in prostate cancer is mediated by HIF-1. Oncotarget. 6:40247–40254. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG, Chang C, et al: NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol. 175:489–499. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Binai NA, Damert A, Carra G, Steckelbroeck S, Löwer J, Löwer R and Wessler S: Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells. Int J Cancer. 127:55–66. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang HC, Yeh HH, Huang WL, Lin CC, Su WP, Chen HHW, Lai WW and Su WC: Activation of the signal transducer and activator of transcription 3 pathway up-regulates estrogen receptor-beta expression in lung adenocarcinoma cells. Mol Endocrinol. 25:1145–1158. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamoto T, Sato N, Sekine Y, Yumioka T, Imoto S, Junicho A, Fuse H and Matsuda T: Molecular interactions between STAT3 and protein inhibitor of activated STAT3, and androgen receptor. Biochem Biophys Res Commun. 306:610–615. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Csabai L, Fazekas D, Kadlecsik T, Szalay-Bekő M, Bohár B, Madgwick M, Módos D, Ölbei M, Gul L, Sudhakar P, et al: SignaLink3: A multi-layered resource to uncover tissue-specific signaling networks. Nucleic Acids Res. 50(D1): D701–D709. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Lin Z, Yin P, Reierstad S, O'Halloran M, Coon VJS, Pearson EK, Mutlu GM and Bulun SE: Adenosine A1 receptor, a target and regulator of estrogen receptoralpha action, mediates the proliferative effects of estradiol in breast cancer. Oncogene. 29:1114–1122. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Xu J, Wu F, Zhu Y, Wu T, Cao T, Gao W, Liu M, Qian W, Feng G, Xi X and Hou S: ANGPTL4 regulates ovarian cancer progression by activating the ERK1/2 pathway. Cancer Cell Int. 24:542024. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao N, Peacock SO, Lo CH, Heidman LM, Rice MA, Fahrenholtz CD, Greene AM, Magani F, Copello VA, Martinez MJ, et al: Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. Sci Transl Med. 11:eaaw46362019. View Article : Google Scholar : PubMed/NCBI | |
|
Guan B, Ma J, Yang Z, Yu F and Yao J: LncRNA NCK1-AS1 exerts oncogenic property in gastric cancer by targeting the miR-22-3p/BCL9 axis to activate the Wnt/β-catenin signaling. Environ Toxicol. 36:1640–1653. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Feng M, Xiao T, Guo B, Liu D, Liu C, Pei J, Liu Q, Xiao Y, Rosin-Arbesfeld R, et al: BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer. Oncogene. 40:2982–2997. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Li P, Miao C, Liang C, Shao P, Wang Z and Li J: Silencing CAPN2 expression inhibited castration-resistant prostate cancer cells proliferation and invasion via AKT/mTOR signal pathway. Biomed Res Int. 2017:25936742017.PubMed/NCBI | |
|
Fang X, Hong Y, Dai L, Qian Y, Zhu C, Wu B and Li S: CRH promotes human colon cancer cell proliferation via IL-6/JAK2/STAT3 signaling pathway and VEGF-induced tumor angiogenesis. Mol Carcinog. 56:2434–2445. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jin C, Han-Hua D, Qiu-Meng L, Deng N, Peng-Chen D, Jie M, Lei X, Xue-Wu Z, Hui-Fang L, Yan C, et al: MTDH-stabilized DDX17 promotes tumor initiation and progression through interacting with YB1 to induce EGFR transcription in hepatocellular carcinoma. Oncogene. 42:169–183. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z, Song Y, Li P and Gao W: GRIN2D knockdown suppresses the progression of lung adenocarcinoma by regulating the E2F signalling pathway. Cell Signal. 107:1106852023. View Article : Google Scholar : PubMed/NCBI | |
|
Yan T, Huang L, Yan Y, Zhong Y, Xie H and Wang X: MAPK/AP-1 signaling pathway is involved in the protection mechanism of bone marrow mesenchymal stem cells-derived exosomes against ultraviolet-induced photoaging in human dermal fibroblasts. Skin Pharmacol Physiol. 36:98–106. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Z, Peng G, Li E, Xi S, Zhang Y, Li Y, Lin X, Li G, Wu Q and He J: MAP kinase-interacting serine/threonine kinase 2 promotes proliferation, metastasis, and predicts poor prognosis in non-small cell lung cancer. Sci Rep. 7:106122017. View Article : Google Scholar : PubMed/NCBI | |
|
Gupta A, Hossain MM, Miller N, Kerin M, Callagy G and Gupta S: NCOA3 coactivator is a transcriptional target of XBP1 and regulates PERK-eIF2α-ATF4 signalling in breast cancer. Oncogene. 35:5860–5871. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Baquié M, St-Onge L, Kerr-Conte J, Cobo-Vuilleumier N, Lorenzo PI, Jimenez Moreno CM, Cederroth CR, Nef S, Borot S, Bosco D, et al: The liver receptor homolog-1 (LRH-1) is expressed in human islets and protects {beta}-cells against stress-induced apoptosis. Hum Mol Genet. 20:2823–2833. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu J, Zou Z, Nie P, Kou X, Wu B, Wang S, Song Z and He J: Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression. Cell Death Dis. 7:e24542016. View Article : Google Scholar : PubMed/NCBI | |
|
Kao TW, Chen HH, Lin J, Wang TL and Shen YA: PBX1 as a novel master regulator in cancer: Its regulation, molecular biology, and therapeutic applications. Biochim Biophys Acta Rev Cancer. 1879:1890852024. View Article : Google Scholar : PubMed/NCBI | |
|
Elix C, Pal SK and Jones JO: The role of peroxisome proliferator-activated receptor gamma in prostate cancer. Asian J Androl. 20:238–243. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Carotenuto M, De Antonellis P, Liguori L, Benvenuto G, Magliulo D, Alonzi A, Turino C, Attanasio C, Damiani V, Bello AM, et al: H-Prune through GSK-3β interaction sustains canonical WNT/β-catenin signaling enhancing cancer progression in NSCLC. Oncotarget. 5:5736–5749. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Teng F, Zhang JX, Chen Y, Shen XD, Su C, Guo YJ, Wang PH, Shi CC, Lei M, Cao YO and Liu SQ: LncRNA NKX2-1-AS1 promotes tumor progression and angiogenesis via upregulation of SERPINE1 expression and activation of the VEGFR-2 signaling pathway in gastric cancer. Mol Oncol. 15:1234–1255. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Sun G, Wei Y, Zhou B, Wang M, Luan R, Bai Y, Li H, Wang S, Zheng D, Wang C, et al: BAP18 facilitates CTCF-mediated chromatin accessible to regulate enhancer activity in breast cancer. Cell Death Differ. 30:1260–1278. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Pospiech K, Orzechowska M, Nowakowska M, Anusewicz D, Płuciennik E, Kośla K and Bednarek AK: TGFα-EGFR pathway in breast carcinogenesis, association with WWOX expression and estrogen activation. J Appl Genet. 63:339–359. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Maeda A, Nishino T, Matsunaga R, Yokoyama A, Suga H, Yagi T and Konishi H: Transglutaminase-mediated cross-linking of WDR54 regulates EGF receptor-signaling. Biochim Biophys Acta Mol Cell Res. 1866:285–295. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cao L, Petrusca DN, Satpathy M, Nakshatri H, Petrache I and Matei D: Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis. 29:1893–1900. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Qian Y, Liu X, Feng Y, Li X and Xuan Y: Tenascin C regulates cancer cell glycolysis and tumor progression in prostate cancer. Int J Urol. 29:578–585. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Wei L, Sun C, Zhang Y, Han N and Sun S: miR-503-5p inhibits colon cancer tumorigenesis, angiogenesis, and lymphangiogenesis by directly downregulating VEGF-A. Gene Ther. 29:28–40. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao L, Parolia A, Qiao Y, Bawa P, Eyunni S, Mannan R, Carson SE, Chang Y, Wang X, Zhang Y, et al: Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature. 601:434–439. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Kim YC, Chen C and Bolton EC: Androgen receptor-mediated growth suppression of HPr-1AR and PC3-Lenti-AR prostate epithelial cells. PLoS One. 10:e01382862015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou D, Chen B, Ye JJ and Chen S: A novel crosstalk mechanism between nuclear receptor-mediated and growth factor/Ras-mediated pathways through PNRC-Grb2 interaction. Oncogene. 23:5394–5404. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Huang YL, Chou WC, Hsiung CN, Hu LY, Chu HW and Shen CY: FGFR2 regulates Mre11 expression and double-strand break repair via the MEK-ERK-POU1F1 pathway in breast tumorigenesis. Hum Mol Genet. 24:3506–3517. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hua S, Kittler R and White KP: Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell. 137:1259–1271. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
O'Neill CF, Urs S, Cinelli C, Lincoln A, Nadeau RJ, León R, Toher J, Mouta-Bellum C, Friesel RE and Liaw L: Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 ×enograft growth. Am J Pathol. 171:1023–1036. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Xiu MX and Liu YM: The role of oncogenic Notch2 signaling in cancer: A novel therapeutic target. Am J Cancer Res. 9:837–854. 2019.PubMed/NCBI | |
|
Shen T, Wang W, Zhou W, Coleman I, Cai Q, Dong B, Ittmann MM, Creighton CJ, Bian Y, Meng Y, et al: MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT. J Clin Invest. 131:e1354652021. View Article : Google Scholar : PubMed/NCBI | |
|
Ross-Innes CS, Brown GD and Carroll JS: A co-ordinated interaction between CTCF and ER in breast cancer cells. BMC Genomics. 12:5932011. View Article : Google Scholar : PubMed/NCBI | |
|
Yang SZ and Abdulkadir SA: Early growth response gene 1 modulates androgen receptor signaling in prostate carcinoma cells. J Biol Chem. 278:39906–39911. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Grinshpun A, Chen V, Sandusky ZM, Fanning SW and Jeselsohn R: ESR1 activating mutations: From structure to clinical application. Biochim Biophys Acta Rev Cancer. 1878:1888302023. View Article : Google Scholar : PubMed/NCBI | |
|
Barker R, Biernacka K, Kingshott G, Sewell A, Gwiti P, Martin RM, Lane JA, McGeagh L, Koupparis A, Rowe E, et al: Associations of CTCF and FOXA1 with androgen and IGF pathways in men with localized prostate cancer. Growth Horm IGF Res. 69–70. 1015332023. | |
|
Pu J, Zhang D, Wang B, Zhu P, Yang W, Wang K, Yang Z and Song Q: FOXA1/UBE2T inhibits CD8+T cell activity by inducing mediates glycolysis in lung adenocarcinoma. Front Biosci (Landmark Ed). 29:1342024. View Article : Google Scholar : PubMed/NCBI | |
|
Vaclavicek A, Bermejo JL, Schmutzler RK, Sutter C, Wappenschmidt B, Meindl A, Kiechle M, Arnold N, Weber BHF, Niederacher D, et al: Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: Putative association of the STAT gene region with familial breast cancer. Endocr Relat Cancer. 14:267–277. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Xu WF, Ma YC, Ma HS, Shi L, Mu H, Ou WB, Peng J, Li TT, Qin T, Zhou HM, et al: Co-targeting CK2α and YBX1 suppresses tumor progression by coordinated inhibition of the PI3K/AKT signaling pathway. Cell Cycle. 18:3472–3490. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Xu M, Jia W, Duan Y, Ma J and Tai W: PU.1 negatively regulates tumorigenesis in non-small-cell lung cancer. Med Oncol. 40:792023. View Article : Google Scholar : PubMed/NCBI | |
|
Tortorella E, Giantulli S, Sciarra A and Silvestri I: AR and PI3K/AKT in prostate cancer: A tale of two interconnected pathways. Int J Mol Sci. 24:20462023. View Article : Google Scholar : PubMed/NCBI | |
|
Hua S, Kallen CB, Dhar R, Baquero MT, Mason CE, Russell BA, Shah PK, Liu J, Khramtsov A, Tretiakova MS, et al: Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol. 4:1882008. View Article : Google Scholar : PubMed/NCBI | |
|
Taslim C, Chen Z, Huang K, Huang TH, Wang Q and Lin S: Integrated analysis identifies a class of androgen-responsive genes regulated by short combinatorial long-range mechanism facilitated by CTCF. Nucleic Acids Res. 40:4754–4764. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Li S, Zhou R, Dong T, Zhang X, Yu M, Lin J, Shi M, Geng E, Li J, et al: SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway. Cancer Lett. 585:2166672024. View Article : Google Scholar : PubMed/NCBI | |
|
Stelzer G, Rosen R, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, Stein TI, Nudel R, Lieder I, Mazor Y, et al: The GeneCards suite: From gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics. 54:1.30.1–1.30.33. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Montes-de-Oca-Fuentes EV, Jácome-López K, Zarco-Mendoza A, Guerrero G, Ventura-Gallegos JL, Juárez-Méndez S, Cabrera-Quintero AJ, Recillas-Targa F and Zentella-Dehesa A: Differential DNA methylation and CTCF binding between the ESR1 promoter a of MCF-7 and MDA-MB-231 breast cancer cells. Mol Biol Rep. 51:1482024. View Article : Google Scholar : PubMed/NCBI | |
|
Rossi EL, Dunlap SM, Bowers LW, Khatib SA, Doerstling SS, Smith LA, Ford NA, Holley D, Brown PH, Estecio MR, et al: Energy balance modulation impacts epigenetic reprogramming, ERα and ERβ expression, and mammary tumor development in MMTV-neu transgenic mice. Cancer Res. 77:2500–2511. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chaudhary S, Krishna BM and Mishra SK: A novel FOXA1/ESR1 interacting pathway: A study of Oncomine™ breast cancer microarrays. Oncol Lett. 14:1247–1264. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Huang YX, Wang DL, Yang B, Yan HY, Lin LH, Li Y, Chen J, Xie LM, Huang YS, et al: LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network. Theranostics. 10:10823–10837. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Y, Li Z, Wedn AM, Casey AN, Brown D, Rao SV, Omarjee S, Hooda J, Carroll JS, Gertz J, et al: FOXA1 reprogramming dictates retinoid X receptor response in ESR1-mutant breast cancer. Mol Cancer Res. 21:591–604. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS and Brown M: FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell. 132:958–970. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Rangel N, Fortunati N, Osella-Abate S, Annaratone L, Isella C, Catalano MG, Rinella L, Metovic J, Boldorini R, Balmativola D, et al: FOXA1 and AR in invasive breast cancer: New findings on their co-expression and impact on prognosis in ER-positive patients. BMC Cancer. 18:7032018. View Article : Google Scholar : PubMed/NCBI | |
|
Seachrist DD, Anstine LJ and Keri RA: FOXA1: A pioneer of nuclear receptor action in breast cancer. Cancers (Basel). 13:52052021. View Article : Google Scholar : PubMed/NCBI | |
|
Tsirigoti C, Ali MM, Maturi V, Heldin CH and Moustakas A: Loss of SNAI1 induces cellular plasticity in invasive triple-negative breast cancer cells. Cell Death Dis. 13:8322022. View Article : Google Scholar : PubMed/NCBI | |
|
Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T, Müntener M and Kristiansen G: FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am J Pathol. 180:848–861. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jin HJ, Zhao JC, Ogden I, Bergan RC and Yu J: Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Res. 73:3725–3736. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Tuteja G, Schug J and Kaestner KH: Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell. 148:72–83. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ross-Innes CS, Stark R, Holmes KA, Schmidt D, Spyrou C, Russell R, Massie CE, Vowler SL, Eldridge M and Carroll JS: Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev. 24:171–182. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Salvatori L, Ravenna L, Caporuscio F, Principessa L, Coroniti G, Frati L, Russo MA and Petrangeli E: Action of retinoic acid receptor on EGFR gene transactivation and breast cancer cell proliferation: Interplay with the estrogen receptor. Biomed Pharmacother. 65:307–312. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Gorodetska I, Offermann A, Püschel J, Lukiyanchuk V, Gaete D, Kurzyukova A, Freytag V, Haider MT, Fjeldbo CS, Di Gaetano S, et al: ALDH1A1 drives prostate cancer metastases and radioresistance by interplay with AR- and RAR-dependent transcription. Theranostics. 14:714–737. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Zou A, Marschke KB, Arnold KE, Berger EM, Fitzgerald P, Mais DE and Allegretto EA: Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. Mol Endocrinol. 13:418–430. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Magnani L, Patten DK, Nguyen VT, Hong SP, Steel JH, Patel N, Lombardo Y, Faronato M, Gomes AR, Woodley L, et al: The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer. Oncotarget. 6:21878–21891. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Magnani L, Ballantyne EB, Zhang X and Lupien M: PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer. PLoS Genet. 7:e10023682011. View Article : Google Scholar : PubMed/NCBI | |
|
Kikugawa T, Kinugasa Y, Shiraishi K, Nanba D, Nakashiro KI, Tanji N, Yokoyama M and Higashiyama S: PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation. Prostate. 66:1092–1099. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Shen T, Dong B, Meng Y, Moore DD and Yang F: A COP1-GATA2 axis suppresses AR signaling and prostate cancer. Proc Natl Acad Sci USA. 119:e22053501192022. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Zhang Q, Li S, Devarajan R, Luo B, Tan Z, Wang Z, Giannareas N, Wenta T, Ma W, et al: GATA2 co-opts TGFβ1/SMAD4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression. J Exp Clin Cancer Res. 42:1982023. View Article : Google Scholar : PubMed/NCBI | |
|
Chaytor L, Simcock M, Nakjang S, Heath R, Walker L, Robson C, Jones D and Gaughan L: The pioneering role of GATA2 in androgen receptor variant regulation is controlled by bromodomain and extraterminal proteins in castrate-resistant prostate cancer. Mol Cancer Res. 17:1264–1278. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, He X, Ngeow J and Eng C: GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. Hum Mol Genet. 21:569–576. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Treeck O, Diepolder E, Skrzypczak M, Schüler-Toprak S and Ortmann O: Knockdown of estrogen receptor β increases proliferation and affects the transcriptome of endometrial adenocarcinoma cells. BMC Cancer. 19:7452019. View Article : Google Scholar : PubMed/NCBI | |
|
Konduri SD, Medisetty R, Liu W, Kaipparettu BA, Srivastava P, Brauch H, Fritz P, Swetzig WM, Gardner AE, Khan SA and Das GM: Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc Natl Acad Sci USA. 107:15081–15086. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Fritah A, Saucier C, Mester J, Redeuilh G and Sabbah M: p21WAF1/CIP1 selectively controls the transcriptional activity of estrogen receptor alpha. Mol Cell Biol. 25:2419–2430. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Nishimura FG, Sampaio BB, Komoto TT, da Silva WJ, da Costa MMG, Haddad GI, Peronni KC, Evangelista AF, Hossain M, Dimmock JR, et al: Exploring CDKN1A upregulation mechanisms: Insights into cell cycle arrest induced by NC2603 curcumin analog in MCF-7 breast cancer cells. Int J Mol Sci. 25:49892024. View Article : Google Scholar : PubMed/NCBI | |
|
Mukhopadhyay UK, Oturkar CC, Adams C, Wickramasekera N, Bansal S, Medisetty R, Miller A, Swetzig WM, Silwal-Pandit L, Børresen-Dale AL, et al: TP53 status as a determinant of pro-vs anti-tumorigenic effects of estrogen receptor-beta in breast cancer. J Natl Cancer Inst. 111:1202–1215. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
He Y, Alejo S, Venkata PP, Johnson JD, Loeffel I, Pratap UP, Zou Y, Lai Z, Tekmal RR, Kost ER and Sareddy GR: Therapeutic targeting of ovarian cancer stem cells using estrogen receptor beta agonist. Int J Mol Sci. 23:71592022. View Article : Google Scholar : PubMed/NCBI | |
|
Lee CI, Goodwin A and Wilcken N: Fulvestrant for hormone-sensitive metastatic breast cancer. Cochrane Database Syst Rev. CD0110932017.PubMed/NCBI | |
|
Augusto TV, Amaral C, Varela CL, Bernardo F, da Silva ET, Roleira FFM, Costa S, Teixeira N and Correia-da-Silva G: Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors. J Steroid Biochem Mol Biol. 195:1054862019. View Article : Google Scholar : PubMed/NCBI | |
|
Jacobson EM, Hugo ER, Tuttle TR, Papoian R and Ben-Jonathan N: Unexploited therapies in breast and prostate cancer: Blockade of the prolactin receptor. Trends Endocrinol Metab. 21:691–698. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Basile D, Cinausero M, Iacono D, Pelizzari G, Bonotto M, Vitale MG, Gerratana L and Puglisi F: Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. Cancer Treat Rev. 61:15–22. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bonkhoff H, Fixemer T, Hunsicker I and Remberger K: Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol. 155:641–647. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Robinson JLL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG and Carroll JS: Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 30:3019–3027. 2011. View Article : Google Scholar : PubMed/NCBI |
